Concise Prescribing Info
Gm +ve bacteria only, vancomycin-resistant Enterococcus faecium infections, nosocomial pneumonia caused by Staph aureus (methicillin-susceptible & -resistant strains) or Strep pneumoniae (including multi-drug-resistant strains [MDRSP]). Complicated skin & skin structure infections including diabetic foot infections w/o concomitant osteomyelitis caused by Staph aureus (methicillin-susceptible & -resistant strains), Strep pyogenes or Strep agalactiae. Uncomplicated skin & skin structure infections caused by Staph aureus (methicillin-susceptible only) or Strep pyogenes. Community-acquired pneumonia caused by Strep pneumoniae (including MDRSP) including cases w/ concurrent bacteremia or Staph aureus (methicillin-susceptible only).
Dosage/Direction for Use
FC tab/IV Adult & adolescent (≥12 yr) 600 mg every 12 hr. Childn (birth through 11 yr) 10 mg/kg every 8 hr. Complicated skin & skin structure infections, community-acquired pneumonia, including concurrent bacteremia, nosocomial pneumonia 10-14 days. Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia 14-28 days. Oral Uncomplicated skin & skin structure infections Duration of treatment: 10-14 days. Adult 400 mg every 12 hr. Adolescent (≥12 yr) 600 mg every 12 hr. Childn 5-11 yr 10 mg/kg every 12 hr, <5 yr 10 mg/kg every 8 hr. IV Administer IV infusion over a period of 30-120 min.
May be taken with or without food.
Hypersensitivity. Concomitant use w/ MAOIs (eg, phenelzine, isocarboxazid), directly & indirectly acting sympathomimetics (eg, pseudoephedrine, phenylpropanolamine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergic agents (eg, dopamine, dobutamine), serotonin re-uptake inhibitors, TCAs, serotonin 5-HT1 receptor agonists (triptans), meperidine, buspirone. Uncontrolled HTN, pheochromocytoma, thyrotoxicosis. Patients w/ carcinoid syndrome.
Special Precautions
Monitor CBC wkly especially patients treated for >2 wk, preexisting myelosuppression, receiving concomitant drugs that produce bone marrow suppression or w/ chronic infection who have received previous or concomitant antibiotic therapy. Discontinue therapy if myelosuppression develops or worsens. C. difficile associated diarrhea. Pseudomembranous colitis in patients w/ diarrhea. Lactic acidosis. Serotonin syndrome in concomitant use w/ serotonergic agents. Peripheral & optic neuropathy may occur in patients treated >28 days. Prompt ophth evaluation is recommended if visual impairment symptoms appear; monitor visual function in all patients taking Zyvox for extended periods (≥3 mth) & patients reporting new visual symptoms regardless of length of therapy; peripheral or optic neuropathy. History of seizures. Superinfection may occur during therapy. Uncontrolled HTN, pheochromocytoma, carcinoid syndrome or untreated hyperthyroidism. Do not administer for >28 days. Patients at high risk for life-threatening systemic infections; not for patients w/ catheter-related bloodstream infections. History of HTN. Avoid large quantities of food or beverages w/ high tyramine content. Concomitant use w/ rifampin; cold remedies & decongestants. Pregnancy & lactation.
Adverse Reactions
Moniliasis; pancytopenia, leucopenia, thrombocytopenia, anemia, sideroblastic anemia; anaphylaxis; lactic acidosis; convulsions, peripheral neuropathy, headache, taste alteration; optic neuropathy; vomiting, diarrhea, nausea, abdominal pain, cramps & distension, tongue discoloration, superficial tooth discoloration; bullous skin disorders including severe cutaneous adverse reactions (eg, toxic epidermal necrolysis & Stevens-Johnson syndrome), angioedema, rash, abnormal hematology tests, abnormal liver function test.
Drug Interactions
Reversible enhancement of pressor response to indirect-acting sympathomimetics, vasopressor or dopaminergics may occur. Serotonin syndrome may occur w/ serotonergic agents including antidepressants eg, SSRIs.
MIMS Class
ATC Classification
J01XX08 - linezolid ; Belongs to the class of other antibacterials. Used in the systemic treatment of infections.
FC tab: D; Infusion: S
Zyvox infusion 2 mg/mL
300 mL x 1's
Zyvox FC tab 600 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in